Anest. intenziv. Med. 2021;32(1):25-29 | DOI: 10.36290/aim.2021.012

Gabapentinoids in the perioperative periodReview Article

Gimunová O., Zemanová J.
Klinika anesteziologie, resuscitace a intenzivní medicíny, Fakultní nemocnice Brno a Lékařská fakulta Masarykovy Univerzity v Brně

Multimodal analgesia is predicated on interactions of medicines whereby benefits of combination exceed the risks. Perioperative gabapentinoids have significant adverse effects. Gabapentinoids, when combined with opioids, confer even greater respiratory risk than opioids alone. Routine perioperative administration of gabapentinoids is not more recommended. New clinical trials to evaluate analgesic benefits of gabapentinoids on postoperative pain are very unlikely to provide any new evidence.

Keywords: history of gabapentinoids, evidence of risk, perioperative period, multimodal analgesia.

Published: March 12, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gimunová O, Zemanová J. Gabapentinoids in the perioperative period. Anest. intenziv. Med. 2021;32(1):25-29. doi: 10.36290/aim.2021.012.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kharasch ED, Clark JD, Kheterpal S. Perioperative Gabapentinoids: Deflating the Bubble. Anesthesiology 2020; 133(2): 251-254. doi: https://doi.org/10.1097/ALN.0000000000003394 Go to original source... Go to PubMed...
    2. EMA: List of the Names, Pharmaceutical Forms, Strengths of the Medicinal Products, Route of Administration, Marketing Authorisation Holders in the Member States 2006 [on‑line]. [2020-06-14]. Dostupné z: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Neurontin_30/WC500009308.pdf.
    3. EMA: Summary of Product Characteristics: Lyrica 2009 [on‑line]. [2020-06-14]. Dostupné z: http://www.ema.europa.eu/docs/en GB/document library/EPAR Product Information/human/000546/WC500046602.pdf.
    4. Verret M, Lauzier F, Zarychanski R, Perron C, Savard X, Pinard AM, et al., the Canadian Perioperative Anesthesia Clinical Trials (PACT) Group. Perioperative Use of Gabapentinoids for the Management of Postoperative Acute Pain: A Systematic Review and Meta‑analysis. Anesthesiology 2020; 133(8): 265-279. doi: https://doi.org/10.1097/ALN.0000000000003428. Go to original source... Go to PubMed...
    5. Deljou A, Hedrick SJ, Portner ER, Schroeder DR, Hooten WM, Sprung J, et al. Pattern of perioperative gabapentinoid use and risk for postoperative naloxone administration. British Journal of Anaesthesia 2018; 120(4): 798-806. doi: org/10.1016/j.bja.2017. 11. 113. Go to original source... Go to PubMed...
    6. Torregrosa‑de Juan E, Olagüe‑Díaz P, Royo‑Maicas P, Fernández‑Nájera E, García‑Maset R. Acute renal failure due to gabapentin. A case report and literature review. Nefrologia 2012; 32(1): 130-131. doi: 10.3265/Nefrologia.pre2011.Nov. 11087. Go to original source... Go to PubMed...
    7. Buckley LF, Alsarraf E. Cardiovascular Safety of Gabapentinoids.Current Emergency and Hospital Medicine Reports 2019; 7: 48-52. Go to original source...
    8. Landaluce LO, Carbonell P, Asensio C, Escoda N, Lopez P, Laporte JR. Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population‑Based Cohort Study in an Electronic Prescription Database. Drug Safety 2018; 41(12): 1325-1331. doi: 10.1007/s40264-018-0695-6 Go to original source... Go to PubMed...
    9. Torrance N, Veluchamy A, Zhou Y, Fletcher EH, Moir E, Hebert HL, et al. Trends in gabapentinoid prescribing, co‑prescribing of opioids and benzodiazepines, and associated deaths in Scotland. British Journal of Anaesthesia 2020; 125(2): 159-167. doi: https://doi.org/10.1016/j.bja.2020. 05. 017 Go to original source... Go to PubMed...
    10. Grosshans M, Lemenager T, Vollmert CH, Kaemmerer N, Schreiner R, Mutschler J, et al. Pregabalin abuse among opiate addicted patients. European Journal of Clinical Pharmacology 2013; 69: 2021-2025. Go to original source... Go to PubMed...
    11. Desai K, Carroll I, Asch S, Hernandez‑Boussard T, Ioannidis J. Extremely large outlier treatment effects may be a footprint of bias in trials from less developed countries: randomized trials of gabapentinoids. Journal of Clinical Epidemiology 2019; 106: 80-87. doi: https://doi.org/10.1016/j.jclinepi.2018. 10. 012 Go to original source... Go to PubMed...
    12. Rawal N. Current issues in postoperative pain management. European Journal of Anaesthesiology 2016; 33(3): 160-171. doi: 10.1097/EJA.0000000000000366. Go to original source... Go to PubMed...
    13. FDA in Brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression. [on‑line]. [2020-04-20]. Dostupné z: www.fda.gov/news‑events/fda‑brief/fda‑brief‑fda‑requires‑new‑warnings‑gabapentinoids‑about‑risk‑respiratory‑depression.
    14. FDA warns about serious breathing problems with seizures and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR). [on‑line]. [2020-04-20]. Dostupné z: www.fda.gov/drugs/drug‑safety‑and‑availability/fda‑warns‑about‑serious‑breathing‑problems‑seizure‑and‑nerve‑pain‑medicines‑gabapentin‑neurontin.
    15. Aubrun F, Nouette‑Gaulain K, Fletcher D, Belbachir A, Beloeil H, Carles M, et al. Revision of expert panel's guidelines on postoperative pain management. Anaest Crit Care Pain Med 2019; 38: 405-411. Go to original source... Go to PubMed...

    Return to the content


    Anesteziologie a intenzivní medicína

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.